Applied DNA Sciences, Inc. (NASDAQ:APDN) Short Interest Up 40.4% in January

Applied DNA Sciences, Inc. (NASDAQ:APDN) saw a significant increase in short interest during the month of January. As of January 15th, there was short interest totalling 7,060,000 shares, an increase of 40.4% from the December 31st total of 5,030,000 shares. Based on an average daily volume of 5,960,000 shares, the short-interest ratio is currently 1.2 days.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Applied DNA Sciences stock. Jane Street Group LLC purchased a new stake in Applied DNA Sciences, Inc. (NASDAQ:APDN) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 73,396 shares of the technology company’s stock, valued at approximately $48,000. Jane Street Group LLC owned approximately 0.24% of Applied DNA Sciences as of its most recent SEC filing. Institutional investors own 22.22% of the company’s stock.

Applied DNA Sciences Price Performance

Shares of APDN stock traded down $0.00 on Friday, hitting $0.18. The stock had a trading volume of 512,071 shares, compared to its average volume of 3,570,315. The stock has a market cap of $9.71 million, a price-to-earnings ratio of -0.03 and a beta of 0.40. The business has a 50 day moving average of $0.19 and a 200 day moving average of $0.54. Applied DNA Sciences has a 12-month low of $0.12 and a 12-month high of $14.40.

Applied DNA Sciences (NASDAQ:APDN) last released its quarterly earnings data on Tuesday, December 17th. The technology company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.01. Applied DNA Sciences had a negative net margin of 203.76% and a negative return on equity of 111.18%. As a group, research analysts expect that Applied DNA Sciences will post -0.87 earnings per share for the current fiscal year.

About Applied DNA Sciences

Applied DNA Sciences, Inc, a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. It operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services.